Sofinnova News
Sofinnova Crossover & Sofinnova Industrial Biotech
Sofinnova Partners’ Antoine Papiernik spoke with In Vivo magazine’s William Looney on European #venturecapital, #investment strategy, and more. https://bit.ly/2GIP9rZ @INVIVOnow @BillInVivo
Sofinnova Partners’ Antoine Papiernik spoke with In Vivo magazine’s William Looney on European #venturecapital, #investment strategy, and more. https://bit.ly/2GIP9rZ @INVIVOnow @BillInVivo
Related Strategy
CrossoverRelated Deal lead
Antoine Papiernik
Related News
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion
Micropep Files First Regulatory Submissions for Promisin™, a Novel Peptide Biofungicide with a New Mode of Action
How a Sofinnova Partner's thesis became a $165M biotech
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
Germany’s top research institutions and venture capital investors unite behind spin-off framework